Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 6/20 | 0.74 |
| ▸ | PKM | P14618 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | PKLR | P30613 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16311216 | 0.86 | ALDH1A1 (0.58) | CCR6PKMSMN1; SMN2HTTGAA | |
| SCHEMBL17303771 | 0.79 | TSHR (0.64) | CCR6GAACYP2C19MAPTKMT2A | |
| SCHEMBL7094586 | 0.75 | CA12 (0.64) | CCR6PKMSMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1147229 | 0.75 | KDM4E (0.55) | SMN1; SMN2CYP1A2CYP3A4GAAMAPT | |
| SCHEMBL23178943 | 0.74 | PKM (0.75) | CCR6PKMSMN1; SMN2HTTGAA | |
| SCHEMBL31155671 | 0.74 | EPHX2 (0.59) | CCR6PKMHTTKMT2AMEN1 | |
| SCHEMBL1722721 | 0.73 | PKM (1.00) | PKMSMN1; SMN2HTTGAAMAPT | |
| SCHEMBL31315853 | 0.73 | PKM (1.00) | PKMSMN1; SMN2HTTGAAMAPT | |
| SCHEMBL12189232 | 0.73 | ALDH1A1 (0.72) | SMN1; SMN2HTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL7471529 | 0.73 | PKM (0.73) | CCR6PKMSMN1; SMN2HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| EP-2939999-B1 | HIGH-PURITY MONOALKENYL-CONTAINING GLYCERIN DERIVATIVE, AND METHOD FOR PRODUCING SAME | DOW CORNING TORAY CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-9663432-B2 | High-purity monoalkenyl-containing glycerin derivative and method of manufacturing same | DOW CORNING TORAY CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20160052849-A1 | High-Purity Monoalkenyl-Containing Glycerin Derivative, And Method For Producing Same | Dow Coming Toray Co., Ltd. (JP) | 2016-02-25 | — | — | US | disclosed |
| EP-2968285-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | Flatley Discovery Lab (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2939999-A1 | HIGH-PURITY MONOALKENYL-CONTAINING GLYCERIN DERIVATIVE, AND METHOD FOR PRODUCING SAME | Dow Corning Toray Co., Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-20140371330-A1 | Novel Co-Modified Organopolysiloxane, And Treatment Agent And External Use Preparation Comprising The Same | DOW TORAY CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| WO-2014160478-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160478-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | CCR6 240/4885PKM 1872/4885SMN1; SMN2 3019/4885 |
| US-20140371330-A1 | Novel Co-Modified Organopolysiloxane, And Treatment Agent And External Use Preparation Comprising The Same | H1-0, H1-2, F12 | CCR6 1357/4885PKM 2885/4885SMN1; SMN2 542/4885 |
| US-20160052849-A1 | High-Purity Monoalkenyl-Containing Glycerin Derivative, And Method For Producing Same | GK, GYPA, NOTUM | CCR6 3982/4885PKM 359/4885SMN1; SMN2 3904/4885 |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | CCR6 240/4885PKM 1872/4885SMN1; SMN2 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.